LifeStance Health Group (NASDAQ:LFST) Releases Earnings Results, Beats Estimates By $0.03 EPS

LifeStance Health Group (NASDAQ:LFST) announced its quarterly earnings data on Thursday. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03, FiscalAI reports. The business had revenue of $435.35 million during the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.LifeStance Health Group’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.01) EPS.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Positive Sentiment: LifeStance reported strong second-quarter performance, with revenue up 26% to $435 million, visits rising 19% to 2.6 million, and Adjusted EBITDA nearly doubling to $66 million. Adjusted EBITDA margin reached 15.2%, up more than 500 basis points year over year.
• Positive Sentiment: Management raised full-year 2026 guidance, now projecting revenue of $1.685 billion-$1.725 billion and Adjusted EBITDA of $215 million-$235 million. The midpoint implies 20% revenue growth and a 13.2% Adjusted EBITDA margin.
• Positive Sentiment: Clinician additions and productivity remain key growth drivers, with 193 net clinicians added in the quarter to reach 8,542, while visits per average clinician increased 7% for the third consecutive quarter. Management said only about 70% of clinician-provided capacity is currently being utilized, indicating further runway.
• Positive Sentiment: Specialty services, including TMS and SPRAVATO, are expanding and generated roughly $50 million of revenue last year, with expected growth of about 40% in 2026. The company also sees significant opportunity from geographic expansion, tuck-in acquisitions, AI-enabled tools, and a planned 2027 EHR rollout.
• Negative Sentiment: Third-quarter Adjusted EBITDA guidance of $49 million-$59 million implies a sequential decline as LifeStance increases spending on technology, patient acquisition, clinical excellence, compensation, and support staff. Management also cautioned that the phased EHR implementation could cause a temporary productivity dip.

LifeStance Health Group Trading Up 1.7%

Shares of LifeStance Health Group stock traded up $0.18 on Friday, hitting $10.84. The stock had a trading volume of 3,793,084 shares, compared to its average volume of 3,253,660. The stock has a 50 day moving average of $9.95 and a 200 day moving average of $8.05. LifeStance Health Group has a twelve month low of $3.90 and a twelve month high of $11.76. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.38. The firm has a market capitalization of $4.20 billion, a P/E ratio of 83.39 and a beta of 1.14.

Key LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: BTIG raises price target: BTIG Research raised its LFST price target from $15 to $16 and initiated a “buy” rating, implying substantial potential appreciation from the referenced $10.84 price. Benzinga price target report
• Positive Sentiment: Q2 earnings beat expectations: LifeStance reported adjusted earnings of $0.06 per share, exceeding the $0.03 consensus estimate, compared with a $0.01 loss in the year-earlier quarter. Revenue rose 26.1% year over year to approximately $435.4 million, ahead of the $414.6 million analyst forecast. LifeStance Q2 earnings report
• Positive Sentiment: Profitability improved sharply: Net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volume increased 19% and the clinician base grew 11% to 8,542, supporting the company’s growth outlook. LifeStance financial results release
• Positive Sentiment: Full-year outlook raised: Management increased 2026 revenue guidance to $1.685 billion-$1.725 billion, Center Margin guidance to $570 million-$594 million and adjusted EBITDA guidance to $215 million-$235 million. Third-quarter revenue is projected at $420 million-$440 million, above the $417.7 million consensus estimate.
• Positive Sentiment: Share repurchase authorization: The board approved a new program allowing up to $100 million of common-stock repurchases, potentially supporting per-share results and signaling management confidence in the company’s valuation.
• Neutral Sentiment: Balance-sheet considerations: LifeStance generated $99.9 million of operating cash flow in Q2 and ended the period with $225.9 million in cash, but reported $259.0 million of net long-term debt.
• Negative Sentiment: Insider selling remains a risk: Recent disclosed insider activity has consisted entirely of sales, including substantial transactions by TPG-related entities and company executives. Continued selling could temper investor enthusiasm despite the strong operating results.

Insider Buying and Selling

In other LifeStance Health Group news, Director Eric Shuey sold 243,362 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the sale, the director directly owned 867,562 shares of the company’s stock, valued at $6,957,847.24. The trade was a 21.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director directly owned 23,310,115 shares in the company, valued at $186,947,122.30. The trade was a 20.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 7,612,394 shares of company stock worth $62,938,451 in the last ninety days. Company insiders own 3.50% of the company’s stock.

Institutional Trading of LifeStance Health Group

Several institutional investors have recently modified their holdings of LFST. Invesco Ltd. raised its position in LifeStance Health Group by 6.9% during the 4th quarter. Invesco Ltd. now owns 205,486 shares of the company’s stock worth $1,447,000 after purchasing an additional 13,177 shares during the last quarter. Vident Advisory LLC lifted its holdings in LifeStance Health Group by 148.8% during the 4th quarter. Vident Advisory LLC now owns 37,462 shares of the company’s stock worth $264,000 after buying an additional 22,406 shares during the period. XTX Topco Ltd bought a new stake in shares of LifeStance Health Group in the 4th quarter valued at about $96,000. Zacks Investment Management grew its position in shares of LifeStance Health Group by 33.1% in the 4th quarter. Zacks Investment Management now owns 45,291 shares of the company’s stock valued at $319,000 after buying an additional 11,270 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of LifeStance Health Group by 58.8% in the fourth quarter. Janus Henderson Group PLC now owns 94,500 shares of the company’s stock valued at $666,000 after buying an additional 35,000 shares during the period. Institutional investors own 85.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on LFST. KeyCorp increased their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Barclays raised their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.62.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.